5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE

The invention relates to a method of inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal comprising administering to said mammal a therapeutically effective amount of an imidazopyridine of formula I with anti-hyperproliferative activity. 2. A compound of where the compound is the free base. This application is a continuation of U.S. Ser. No. 13/586,147, filed Aug. 15, 2012 which is a continuation of U.S. Ser. No. 13/041,735, filed Mar. 7, 2011 which is a divisional application of U.S. Pat. No. 7,923,456, issued Apr. 12, 2011, which claims the benefit of priority to international application number PCT/US2008/087482 and to U.S. provisional Application Ser. No. 61/015,129, filed 19 Dec. 2007, and to U.S. provisional Application Ser. No. 61/054,014, filed 16 May 2008, the disclosures of all are incorporated herein by reference in their entirety.The invention relates to imidazopyridines with anti-cancer activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.In the quest to understand how Ras transmits extracellular growth signals, the MAP (mitogen-activated protein) kinase (MAPK) pathway has emerged as the crucial route between membrane-bound Ras and the nucleus. The MAPK pathway encompasses a cascade of phosphorylation events involving three key kinases, namely Raf, MEK (MAP kinase kinase) and ERK (MAP kinase). Active GTP-bound Ras results in the activation and indirect phosphorylation of Raf kinase. Raf then phosphorylates MEK1 and 2 on two serine residues (S218 and 5222 for MEK1 and S222 and 5226 for MEK2) (Ahn et al., 2001, 332, 417-431). Activated MEK then phosphorylates its only known substrates, the MAP kinases, ERK1 and 2. ERK phosphorylation by MEK occurs on Y204 and T202 for ERK1 and Y185 and T183 for ERK2 (Ahn et al., ...

PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R, Rand Rare defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed. 2. The compound of claim 1 , wherein Ris hydrogen or —NH.3. The compound of claim 1 , wherein Ris selected from pyrazolyl or thiazolyl optionally substituted with 1-3 R.5. The compound of claim 1 , wherein Ris independently —(C-Calkyl)OR claim 1 , —(C-Calkyl)SR claim 1 , halogen claim 1 , —(C-Calkyl)CN claim 1 , C-Calkyl claim 1 , C-Calkenyl or C-Calkynyl claim 1 , —(C-Calkyl)C(O)OR claim 1 , —(C-Calkyl)C(O)NRNR claim 1 , —(C-Calkyl)OC(O)NR claim 1 , —(C-Calkyl)NRC(O)OR claim 1 , —(C-Calkyl)NRC(O)NRor —(C-Calkyl)NRC(O)R claim 1 , —(C-Calkyl)(C-Ccycloalkyl) claim 1 , —(C-Calkyl)C(O)(3-6-membered heterocyclyl) claim 1 , —(C-Calkyl)(3-6-membered heterocyclyl) claim 1 , —(C-Calkyl)NRRor —(C-Calkyl)CF claim 1 , wherein Ris independently optionally substituted by R.7. The compound of claim 1 , wherein Ris phenyl claim 1 , pyridinyl or 4-6 membered heterocyclyl claim 1 , wherein Ris optionally substituted by R.8. The compound of claim 1 , wherein Ris independently C-Calkyl claim 1 , halogen claim 1 , oxo claim 1 , —CN claim 1 , —(C-Calkyl)OR claim 1 , —(C-Calkyl)SR claim 1 , —(C-Calkyl)NRR claim 1 , —(C-Calkyl)OCFor —CF claim 1 , wherein said alkyl is independently optionally substituted by halogen claim 1 , C-Calkyl claim 1 , oxo claim 1 , —CF claim 1 , —(C-Calkyl)ORor —(C-Calkyl)NRR.10. The compound of claim 1 , wherein Ris phenyl optionally substituted by 1-2 R.12. A compound of claim 1 , enantiomers claim 1 , diastereomers or pharmaceutically acceptable salts thereof claim 1 , wherein ...

PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R, Rand Rare defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed. 2. The compound of claim 1 , wherein Ris hydrogen or —NH.3. The compound of claim 1 , wherein Ris selected from pyrazolyl or thiazolyl optionally substituted with 1-3 R.5. The compound of claim 1 , wherein Ris independently —(C-Calkyl)OR claim 1 , —(C-Calkyl)SR claim 1 , halogen claim 1 , —(C-Calkyl)CN claim 1 , C-Calkyl claim 1 , C-Calkenyl or C-Calkynyl claim 1 , —(C-Calkyl)C(O)OR claim 1 , —(C-Calkyl)C(O)NRNR claim 1 , —(C-Calkyl)OC(O)NR claim 1 , —(C-Calkyl)NRC(O)OR claim 1 , —(C-Calkyl)NRC(O)NRor —(C-Calkyl)NRC(O)R claim 1 , —(C-Calkyl)(C-Ccycloalkyl) claim 1 , —(C-Calkyl)C(O)(3-6-membered heterocyclyl) claim 1 , —(C-Calkyl)(3-6-membered heterocyclyl) claim 1 , —(C-Calkyl)NRRor —(C-Calkyl)CF claim 1 , wherein Ris independently optionally substituted by R.7. The compound of claim 1 , wherein Ris phenyl claim 1 , pyridinyl or 4-6 membered hererocyclyl claim 1 , wherein Ris optionally substituted by R.8. The compound of claim 1 , wherein Ris independently C-Calkyl claim 1 , halogen claim 1 , oxo claim 1 , —CN claim 1 , —(C-Calkyl)OR claim 1 , —(C-Calkyl)SR claim 1 , —(C-Calkyl)NRR claim 1 , (C-Calkyl)OCFor —CF claim 1 , wherein said alkyl is independently optionally substituted by halogen claim 1 , C-Calkyl claim 1 , oxo claim 1 , —CF claim 1 , —(C-Calkyl)ORor —(C-Calkyl)NRR.10. The compound of claim 1 , wherein Ris phenyl optionally substituted by 1-2 R.12. A compound of claim 1 , enantiomers claim 1 , diastereomers or pharmaceutically acceptable salts thereof claim 1 , wherein:{' ...

TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein. 12. A compound of claim 1 , wherein R claim 1 , Rand Rare each hydrogen.13. The compound of claim 1 , wherein Aris phenylene or pyrazolylene.15. The compound of claim 1 , wherein —X—Ris —N(R)—(CRR)—R.16. The compound of claim 15 , wherein:{'sup': 1b', 'x1', 'y1', '1a', '9', 'a', 'b, 'sub': 1', '6', '1', '6', '1', '6', '1', '6, '(1) Ris C-Calkyl optionally substituted by C-Calkoxy, p is 0-3, Rand Rare each independently hydrogen or C-Calkyl, Ris C-Calkyl and Ris NRR; or'}{'sup': 1b', 'x1', 'y1', '1a', '9, 'sub': 1', '6', '1', '6', '1', '6, '(2) Ris C-Calkyl optionally substituted by C-Calkoxy, p is 0-3, Rand Rare each independently hydrogen or C-Calkyl, and Ris 3-11 membered heterocyclyl optionally substituted by R; or'}{'sup': 1a', '1b', '9, '(3) p is 0 and Rand Rare joined to form a 3-11 membered heterocyclyl optionally substituted by R.'}17. The compound of claim 1 , wherein the optional substituents of said optionally substituted C-Calkyl of Ror optionally substituted 3-11 membered heterocyclyl of Rare selected from OH; halogen; CN; NRR; C-Calkyl optionally substituted by halogen; C-Ccycloalkyl; C-Calkoxy; phenyl; 3-11 membered heterocyclyl optionally substituted by C-Calkyl or NRR; C(O)C-Calkyl; and C(O)-3-11 membered heterocyclyl optionally substituted by C-Calkyl.19. The compound of claim 15 , wherein Ris hydrogen or CH.21. A compound selected from Table I claim 15 , Table II claim 15 , or Table III.22. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.23. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient a therapeutically effective amount of a compound of .24. The method of claim 23 , wherein the disease or ...

TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein. 1. A compound selected from the group consisting ofN-methyl-4-[[8-(4-methyl-4-phenyl-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-(1-methyl-4-piperidyl)benzamide;hydrochloride4-[[8-(4-cyclohexyl-4-hydroxy-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide4-[[8-(4-hydroxy-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide;hydrochlorideN-methyl-N-(1-methyl-4-piperidyl)-4-[[8-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]bhenzamide4-[[8-(4-methoxy-4-phenyl-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide;hydrochloride4-[[8-(4-hydroxy-4-methyl-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide;hydrochloride4-[[8-(4-hydroxy-4-phenyl-azepan-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide4-[[8-(4-methoxy-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide4-[[8-(4-acetamido-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide;hydrochloride4-[[8-(4-acetylpiperazin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide4-[[8-(4-cyano-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamideN-methyl-N-(1-methyl-4-piperidyl)-[4-[[8-(1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]benzamide;dihydrochlorideN-methyl-N-(1-methyl-4-piperidyl)-4-[[8-(4-phenylpiperazin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]benzamideN-methyl-N-(1-methyl-4-piperidyl)-4-[[8-(4-phenyl-2,3,6,7-tetrahydroazepin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]benzamideN-methyl-N-(1-methyl-4-piperidyl)-4-[[8-(5-phenyl-2,3,4,7-tetrahydroazepin-1 ...

TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein. 3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein mis 1 and mis 1 claim 1 , or mis 2 and mis 1.4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein:{'sup': 6', '7, 'Rand Rare attached to the ring at the same carbon atom; or'}{'sup': 6', '7, 'sub': 1', '6', '1', '6, 'Ris C-Calkyl or C-C-alkoxy, and Ris optionally substituted phenyl; or'}{'sup': 6', '7', 'a', 'b, 'sub': 1', '6', '3', '6', '0', '6', '0', '6', '0', '6, 'Ris C-Calkyl, C-Ccycloalkyl or optionally substituted phenyl and Ris OH, (C-Calkylene) C(O)NRR, (C-Calkylene) CN or —O— (C-Calkyl)CN; or'}{'sup': 6', '7', 'a', 'b', 'a', 'b, 'sub': 0', '6', '0', '6', '1', '6', '3', '6', '0', '6', '1', '6, 'Ris hydrogen and Ris selected from (C-Calkylene) C(O)NRR, (C-Calkylene) CN, C-C-alkoxy, —O—(C-Ccycloalkyl), —O—(C-Calkylene)C(O)NRR, and —O—(C-Calkylene)CN; or'}{'sup': 6', '7, 'Rand Rtogether form a 3-11 membered heterocycloalkyl optionally substituted by oxo.'}6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein one or both of Rand Ris located at the para position of the ring.8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein mis 1 and mis 2 claim 1 , or mis 2 and mis 1 claim 1 , or mis 1 and mis 1.9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris H and Rand is substituted phenyl.12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof claim 11 , wherein mis 1 and mis 1 claim 11 , or mis 1 and mis 2 claim 11 , or mis 1 and mis 0.15. The compound of claim 14 , or a pharmaceutically acceptable salt thereof claim 14 , wherein mis 1 and mis 1 claim 14 , mis 1 and mis 1 claim 14 , or mis 1 and mis 2.16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim ...

PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R, Rand Rare defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed. 2. The compound of claim 1 , wherein Ris hydrogen or —NH.3. The compound of claim 1 , wherein Ris selected from pyrazolyl or thiazolyl optionally substituted with 1-3 R.5. The compound of claim 1 , wherein Ris independently —(C-Calkyl)OR claim 1 , —(C-Calkyl)SR claim 1 , halogen claim 1 , —(C-Calkyl)CN claim 1 , C-Calkyl claim 1 , C-Calkenyl or C-Calkynyl claim 1 , —(C-Calkyl)C(O)OR claim 1 , —(C-Calkyl)C(O)NRNR claim 1 , —(C-Calkyl)OC(O)NR claim 1 , —(C-Calkyl)NRC(O)OR claim 1 , —(C-Calkyl)NRC(O)NRor —(C-Calkyl)NRC(O)R claim 1 , —(C-Calkyl)(C-Ccycloalkyl) claim 1 , —(C-Calkyl)C(O)(3-6-membered heterocyclyl) claim 1 , —(C-Calkyl)(3-6-membered heterocyclyl) claim 1 , —(C-Calkyl)NRRor —(C-Calkyl)CF claim 1 , wherein Ris independently optionally substituted by R.7. The compound of claim 1 , wherein Ris phenyl claim 1 , pyridinyl or 4-6 membered hererocyclyl claim 1 , wherein Ris optionally substituted by R.8. The compound of claim 1 , wherein Ris independently C-Calkyl claim 1 , halogen claim 1 , oxo claim 1 , —CN claim 1 , —(C-Calkyl)OR claim 1 , —(C-Calkyl)SR claim 1 , —(C-Calkyl)NRR claim 1 , —(C-Calkyl)OCFor —CF claim 1 , wherein said alkyl is independently optionally substituted by halogen claim 1 , C-Calkyl claim 1 , oxo claim 1 , —CF claim 1 , —(C-Calkyl)ORor —(C-Calkyl)NRR.10. The compound of claim 1 , wherein Ris phenyl optionally substituted by 1-2 R.12. A compound of claim 1 , enantiomers claim 1 , diastereomers or pharmaceutically acceptable salts thereof claim 1 , wherein ...

TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein. 3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein mis 1 and mis 1 claim 1 , or is 2 and mis 1.4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein:{'sup': 6', '7, 'Rand Rare attached to the ring at the same carbon atom; or'}{'sup': 6', '7, 'sub': 1', '6', '1', '6, 'Ris C-Calkyl or C-C-alkoxy, and Ris optionally substituted phenyl; or'}{'sup': 6', '7', 'a', 'b, 'sub': 1', '6', '3', '6', '0', '6', '0', '6', '0', '6, 'Ris C-Calkyl, C-Ccycloalkyl or optionally substituted phenyl and Ris OH, (C-Calkylene)C(O)NRR, (C-Calkylene)CN or —O—(C-Calkyl)CN; or'}{'sup': 6', '7', 'a', 'b', 'a', 'b, 'sub': 0', '6', '0', '6', '1', '6', '3', '6', '0', '6', '1', '6, 'Ris hydrogen and Ris selected from (C-Calkylene)C(O)NRR, (C-Calkylene)CN, C-C-alkoxy, —O—(C-Ccycloalkyl), —O—(C-Calkylene)C(O)NRR, and —O—(C-Calkylene)CN; or'}{'sup': 6', '7, 'Rand Rtogether form a 3-11 membered heterocycloalkyl optionally substituted by oxo.'}6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein one or both of Rand Ris located at the para position of the ring.8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein mis 1 and mis 2 claim 1 , or mis 2 and mis 1 claim 1 , or mis 1 and mis 1.9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris H and Rand is substituted phenyl.12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof claim 11 , wherein mis 1 and mis 1 claim 11 , or mis 1 and mis 2 claim 11 , or mis 1 and mis 0.15. The compound of claim 14 , or a pharmaceutically acceptable salt thereof claim 14 , wherein mls 1 and mis 1 claim 14 , mis 1 and mis 1 claim 14 , or mis 1 and mis 2.16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , ...

5-anilinoimidazopyridines and methods of use

5-Anilinoimidazopyridines and Methods of Use

The invention relates to imidazopyridines of formula 1 with anti-cancer and/or anti-inflammatory activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

5-anilinoimidazopyridines and methods of use

5-ANILINOIMIDAZOPYRIDINES AND PROCEDURES FOR THEIR USE

Pyrazolopyrimidine JAK inhibitor compounds and methods

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R, R and R are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.

5-Anilinoimidazopyridines and Methods of Use

Pyrazolopyrimidine jak inhibitor compounds and methods

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.

5-anilinoimidazopyridines and methods of use.

La invención es concerniente con imidazopiridinas de fórmula I con actividad anti-cáncer y/o anti-inflamatoria y más especialmente con imidazopiridinas que inhiben la actividad de cinasa MEK. La invención provee composiciones y métodos útiles para la inhibición del crecimiento anormal de células o tratamiento de enfermedad inflamatoria en un mamífero. La invención también es concerniente con métodos de uso de los compuestos para la diagnosis o tratamiento in vitro, in situ e in vivo de células mamíferas o condiciones patológicas asociadas.

5-Anilinoimidazopyridines and Methods of Use

5-anilinoimidazopyridines and methods of use 5-

JAK DE PIRAZOLOPIRIMIDINA INHIBITING COMPOUNDS AND METHODS

Un compuestos de la fórmula I, enantiómeros, diasteriomeros, tautómeros o sales farmaceúticamente aceptables de los mismos, en donde R1, R2 y R3 son definidos en la presente, son útiles como inhibidores de uno o más quinasas Janus.

Pyrazolopyrimidine jak inhibitor compounds and methods

Disclosed are pyrazolopyrimidine compounds of formula (I) and methods for their preparation. The compounds of formula (I) are Janus kinase (JAK) inhibitors, and useful for treating cancer, polycythaemia Vera, essential thrombocytosis, myelofibrosis, chronic myelogenous leukaemia (CML), rheumatoid arthritis, inflammatory bowel syndrome, Chron’s disease, psoriasis, contact dermatitis or delayed hypersensitivity reactions.

Triazolopyridine compounds, compositions and methods of use thereof

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

5-anilinoimidazopyridines and methods of use

5-anilinoimidazopyridines and methods of use

Pyrazolopyrimidine jak inhibitor compounds and methods

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.

Triazolopyridine compounds, compositions and methods of use thereof

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.